Moving and improving for Omicron

Published: 31-Mar-2010
Manufacturing Finance

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Located in Hungerford, Berkshire, the modern, fully redecorated building will house the office, warehouse and workshop departments of our scientific equipment distribution and support business. For the first time, Omicron’s complete operation will be housed under one roof, providing a more responsive and streamlined service to customers.

A substantial investment has been made into the refurbishment of the new premises and the upgrade of technology, ensuring continuation of the high level of customer service for which Omicron is renowned. With immediate access to the M4, the new location offers staff and clientele a more convenient and professional environment in which to do business.

To coincide with the move the company hase enhanced its website by adding two new functionalities. An extensive parts catalogue is now available on-line, complemented by a new quotation request facility, providing a fast, easy to use service for customers. We invite you to visit and explore our website, www.omicron-uk.com, where you will find information on an extensive range of dissolution, chromatography, spectroscopy, OPLC and capillary electrophoresis products.
See more

You may also like

Manufacturing

HPTLC – a thoroughly modern method

Read more
High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  4. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  5. Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

You may also like

Manufacturing

HPTLC – a thoroughly modern method

High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.
Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Subscribe now